Cancer Drug Parity Act of 2025
Summary
HR4101, the Cancer Drug Parity Act of 2025, aims to equalize patient cost-sharing for oral and intravenously administered anticancer drugs. If enacted, this bill would reduce out-of-pocket costs for patients using oral anticancer medications, likely increasing demand for these treatments. Pharmaceutical companies with significant oral oncology portfolios stand to benefit from enhanced patient access.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR4101 aims to equalize patient cost-sharing for oral and intravenously administered anticancer drugs.
- 2.The bill is in the early stages, having been referred to the House Committee on Education and Workforce.
- 3.If enacted, it would likely increase demand for oral anticancer medications by reducing patient out-of-pocket costs.
- 4.Pharmaceutical companies with strong oral oncology pipelines stand to benefit from increased patient access.
Market Implications
The potential enactment of HR4101 presents a bullish outlook for pharmaceutical companies with substantial oral oncology portfolios. By mandating equal cost-sharing, the bill directly addresses a financial barrier that can limit patient access to these drugs. Companies like Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), Bristol Myers Squibb ($BMY), Amgen ($AMGN), Eli Lilly ($LLY), and Gilead Sciences ($GILD) are positioned to benefit from increased prescription volumes and revenue for their oral anticancer treatments. While the bill is in early stages, its progression would signal a more favorable market environment for these specific drug classes.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Most Favored Patient Act of 2026
Skinny Labels, Big Savings Act
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
Medicare for All Act
To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.